Myelodysplastic Syndrome Pipeline Expands as 120+ Pharma Companies Advance 150+ Novel Blood Cancer Therapies, Finds DelveInsight | Syros Pharmaceuticals, Ryvu Therapeutics, Curis, Minovia Therapeutics, Jazz Pharmaceuticals

DelveInsight's "Myelodysplastic Syndrome - Pipeline Insight, 2026" report provides comprehensive insights about 120+ companies developing several pipeline drugs in the Myelodysplastic Syndrome pipeline landscape. It covers the MDS pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

• Explore the latest breakthroughs in the Myelodysplastic Syndrome treatment landscape. Learn more about the evolving MDS pipeline today @ https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
• Key Takeaways from the Myelodysplastic Syndrome Pipeline Report
• In December 2025, key updates in MDS management from ASH 2025 included new data from the MAXILUS trial, long-term outcomes from the IMerge study, and results from the Phase III VERONA trial evaluating azacitidine plus venetoclax.
• In August 2025, milestone breakthroughs and new drug candidates for Myelodysplastic Syndrome treatment were reported, shaping the future therapeutic landscape.
• In April 2025, Jazz Pharmaceuticals expanded its oncology pipeline through the acquisition of dordaviprone, a therapy previously developed by Chimerix currently in Phase 3 evaluation for mutant diffuse glioma and being explored for other myeloid malignancies.
• Myelodysplastic Syndrome (MDS) represents a group of blood cancers characterized by bone marrow failure and ineffective hematopoiesis, primarily affecting patients over 65 years of age.
• DelveInsight's Myelodysplastic Syndrome Pipeline Insight report depicts a robust clinical development space with over 120 active players advancing 150+ pipeline therapies for MDS across multiple stages, from discovery through Phase III.
• Syros Pharmaceuticals is advancing Tamibarotene, a selective RARα agonist, into Phase III clinical trials for high-risk MDS patients characterized by specific gene overexpression.
• Ryvu Therapeutics is developing RVU120, a highly selective CDK8/CDK19 inhibitor currently in Phase II clinical evaluation for the treatment of MDS and acute myeloid leukemia.
• Curis is evaluating Emavusertib (CA-4948), an oral small-molecule IRAK4 kinase inhibitor, in Phase II trials as a potential targeted therapy for MDS.
• The leading Myelodysplastic Syndrome companies include Syros Pharmaceuticals, Ryvu Therapeutics, Curis, Minovia Therapeutics, Jazz Pharmaceuticals, PharmaMar, Celgene, and Bristol-Myers Squibb.
• Promising Myelodysplastic Syndrome therapies in development include Tamibarotene, RVU120, Emavusertib, and MNV-201, a novel cell therapy utilizing Mitochondrial Augmentation Technology.

Download for updates and the latest revolution in MDS care @ https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Myelodysplastic Syndrome Emerging Drugs Profile

• Tamibarotene: Syros Pharmaceuticals
Tamibarotene is a first-in-class, oral, selective retinoic acid receptor alpha (RARα) agonist. It is currently being evaluated in Phase III clinical trials for the treatment of newly diagnosed, higher-risk MDS patients who exhibit RARA gene overexpression. By targeting this specific genetic profile, Syros Pharmaceuticals aims to provide a more personalized therapeutic option that promotes the differentiation of myeloid cells, potentially improving patient outcomes in high-risk populations.

• RVU120: Ryvu Therapeutics
RVU120 is a selective small-molecule inhibitor of CDK8 and CDK19 kinases developed by Ryvu Therapeutics. These kinases are involved in regulating gene transcription and are often dysregulated in myeloid malignancies. Currently in Phase II clinical evaluation, RVU120 has shown potential in pre-clinical and early clinical studies to inhibit the growth of cancer cells while sparing normal hematopoiesis, offering a novel mechanism for managing patients with relapsed or refractory MDS.

• Emavusertib (CA-4948): Curis
Emavusertib, also known as CA-4948, is an oral small-molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) and FMS-like tyrosine kinase 3 (FLT3). IRAK4 signaling is a key driver of inflammation and cell survival in MDS, particularly in those with spliceosome mutations. Emavusertib is currently in Phase II clinical trials, where it is being studied both as a monotherapy and in combination with other agents to address the unmet needs of patients with high-risk Myelodysplastic Syndrome.

For more information on the Myelodysplastic Syndrome Emerging Drugs Profile, download DelveInsight's comprehensive Myelodysplastic Syndrome Pipeline Insight report @ https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Myelodysplastic Syndrome Pipeline Report Provides

• Detailed insights about companies developing therapies for Myelodysplastic Syndrome, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for MDS treatment.
• MDS companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• MDS drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Myelodysplastic Syndrome market.

Learn more about Myelodysplastic Syndrome drug opportunities in our comprehensive MDS pipeline report @ https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Myelodysplastic Syndrome Companies and Competitive Landscape

There are 120+ key companies, including Syros Pharmaceuticals, Ryvu Therapeutics, Curis, Minovia Therapeutics, Jazz Pharmaceuticals, PharmaMar, and Celgene, developing therapies for Myelodysplastic Syndrome, with several candidates such as Tamibarotene reaching advanced Phase III clinical evaluation.

DelveInsight's Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Myelodysplastic Syndrome products have been categorized under various Molecule types such as:

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Myelodysplastic Syndrome treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Scope of the Myelodysplastic Syndrome Pipeline Report

• Coverage: Global
• Myelodysplastic Syndrome Companies: Syros Pharmaceuticals, Ryvu Therapeutics, Curis, Minovia Therapeutics, Jazz Pharmaceuticals, PharmaMar, and others.
• Myelodysplastic Syndrome Therapies: Tamibarotene, RVU120, Emavusertib, MNV-201, and other undisclosed pipeline candidates.
• Myelodysplastic Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination.
• Myelodysplastic Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.